LabMed

Prothrombin (Factor II) Deficiency – Acquired

At a Glance

Acquired isolated factor II deficiency is associated with factor II inhibitors.

Based on their effect on prothrombin time (PT), partial thromboplastin time (PTT), and 1:1 mixing study, factor II inhibitors may be non-neutralizing or neutralizing.

What Tests Should I Request to Confirm My Clinical Dx? In addition, what follow-up tests might be useful?

The following test results are consistent with acquired isolated factor to deficiency.

For non-neutralizing antibodies to factor to which increase the clearance rate of prothrombin and are usually associated with lupus anticoagulant and bleeding:

  • Prolonged PT and PTT

  • Correction of 1:1 mixing study for the PT and PTT

  • Isolated decrease of factor II activity

For neutralizing antibodies that are associated either with bleeding or with recurrent arterial thrombosis:

  • Prolonged PT and PTT

  • Noncorrection of 1:1 mixing study for the PT and PTT

  • Isolated decrease of factor II activity

Are There Any Factors That Might Affect the Lab Results? In particular, does your patient take any medications - OTC drugs or Herbals - that might affect the lab results?

Acquired prothrombin deficiency is seen in patients with liver disease, vitamin K deficiency (malnutrition, antibiotics), or ingestion of vitamin K antagonists, such as warfarin or superwarfarins. In all of these conditions, all vitamin K-dependent factors, including protein C and protein S, are decreased.

Loading links....
You must be a registered member of ONA to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs